Carrie Smith Cox bought $502K of Organon & (OGN)
Executed Nov 12 2025, disclosed Nov 13 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Nov 13 2025), the stock returned -6.4% (delay-adjusted); from the execution session (Nov 12 2025), -1.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Carrie Smith Cox (Executive Chair) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in Organon & Co. (OGN). Across 1 priced purchase filing, the average 21-session return was -1.6% from execution and -6.4% from disclosure (delay-adjusted; derived). The largest single filing was $2.7M of TXN (8,838 sh across 2 lots, as filed), executed May 13.
Healthcare · Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe,…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→12,469 sh × $8.07
Exec May 14 2025
Filed May 15 2025 · 5:30 PM ET